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Objectives This study sought to understand the prevalence and clinical relevance of iron deficiency in patients with idio-
pathic pulmonary arterial hypertension (IPAH).
Background Iron availability influences the pulmonary vascular response to hypoxia in humans and may be significant in the
pathogenesis of IPAH.
Methods Iron deficiency, defined by raised levels of soluble transferrin receptor (sTfR), was investigated in 98 patients
with IPAH. Hepcidin and erythropoietin (EPO) levels were also measured. The effect of bone morphogenetic pro-
tein (BMP) receptor knockdown on BMP-6–stimulated hepcidin production was assessed in human hepatoma
HepG2 cells. Relationships between sTfR and exercise capacity, functional class, and all-cause mortality were
analyzed.
Results Circulating sTfR levels were raised in 63% of IPAH patients, indicating significant iron deficiency. Consistent with
this, iron, ferritin, and transferrin saturation levels were reduced and red cell distribution width increased, with-
out overt anemia. Hepcidin correlated inversely with sTfR and positively with increasing ferritin. Hepcidin was
inappropriately raised in IPAH independent of the inflammatory marker interleukin-6. EPO levels were also
raised and correlated inversely with hepcidin. BMP receptor-type 2 (BMPR2) knockdown in HepG2 cells in-
creased BMP-6–stimulated hepcidin expression. sTfR increased with World Health Organization functional class
(p  0.05), correlated negatively with exercise capacity (p  0.027), and values 28.1 nmol/l independently
predicted survival (p  0.011).
Conclusions Iron deficiency is common in IPAH patients and associated with disease severity and poor clinical outcome. In-
appropriately raised hepcidin levels, which impair iron absorption from the gut, may be a factor. (J Am Coll
Cardiol 2011;58:300–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.057Pulmonary arterial hypertension (PAH) is characterized by
increased pulmonary vascular resistance due to vasoconstric-
tion, thrombosis, and structural remodeling of pulmonary
arterioles (1). Pressure overload of the right ventricle leads
to progressive hypertrophy and dilation, followed by end-
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2011, accepted February 22, 2011.stage heart failure and death. Therapeutic options have
increased in recent years, but the prognosis remains poor.
There is considerable interest in the role of iron status in
PAH. Iron availability affects pulmonary hemodynamics; the
availability of iron modifies basal pulmonary artery pressure
and the pulmonary vasoconstrictor response to hypoxia in
humans (2–4). Increased red cell distribution width (RDW), a
clinical marker of iron-deficiency anemia, or the presence of
anemia itself, is associated with a poor prognosis in pulmonary
hypertension (5,6). Recently, iron deficiency, defined by re-
duced serum iron and transferrin saturations, was reported in
30 of 70 patients with idiopathic pulmonary arterial hyperten-
sion (IPAH), which correlated negatively with exercise capac-
ity, a surrogate of prognosis. Interestingly, oral iron therapy was
ineffective at restoring normal ferritin levels suggesting a
problem with iron absorption (7).
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July 12, 2011:300–9 Iron Deficiency in IPAHA major regulator of body iron homeostasis is hepcidin,
which acts to reduce dietary iron absorption and increase
cellular iron storage (8). A number of factors may influence
hepcidin levels in PAH. Of particular interest is bone
morphogenetic protein (BMP) signaling. BMP receptor-
type II (BMPR2) expression is reportedly reduced in all
IPAH patients (9), and loss-of-function mutations in
BMPR2 have been linked to 70% of familial PAH and
10% to 20% of IPAH cases (10). BMP signaling regulates
hepatic expression of hepcidin (11–13). BMP-6 has
emerged as the principal BMP regulating hepatic hepcidin
expression in vivo, and its levels are regulated by iron in the
liver and intestine (11–14). Iron stimulates BMP-6 expres-
sion (14), leading to increased hepcidin expression; con-
versely, BMP-6 knockout mice develop severe iron overload
due to markedly reduced hepcidin expression (11). Reduced
BMP signaling would predict raised hepcidin levels in
PAH. Other factors that may affect hepcidin expression in
PAH include inflammatory cytokines, hypoxia, erythropoi-
etic activity, soluble transferrin receptor (sTfR), and growth
differentiation factor (GDF)-15 (8).
We hypothesized that iron deficiency is prevalent and
clinically important in IPAH and that increased hepcidin
expression, possibly related to dysfunctional BMP signaling,
might contribute to this. We investigated the relationship of
iron deficiency to circulating hepcidin levels and survival in
IPAH, and explored potential mechanisms of hepcidin
dysregulation.
Methods
Patient samples. Plasma samples with sufficient volume for
the required analyses were obtained from the Imperial
College Pulmonary Hypertension biorepository. This re-
pository comprises blood samples from consenting patients
with IPAH attending Hammersmith Hospital, London,
between 2002 and 2009. The diagnosis of IPAH was based
on standard criteria with confirmation by right heart cath-
eterization and exclusion of other forms of pulmonary
hypertension (15). Hemodynamic data were acquired at
catheterization. Patients with comorbidities that might
affect iron homeostasis, including hemolytic anemias, ge-
netic disorders of hemoglobin, diabetes, and systemic car-
diovascular disease, were excluded. Survival status was
censored on January 11, 2010. Healthy controls were
recruited from Imperial College London, United Kingdom.
Ethical approval was received from local research ethics
committees. All samples were obtained with informed and
written consent. Blood samples were coincident with mea-
surements of World Health Organization (WHO) func-
tional class, 6-min walk distance, and oxygen saturation.
Plasma samples were collected into ethylenediaminetet-
raacetic acid (EDTA) tubes (chilled on ice) and stored at
80°C. Human liver tissue samples were used to demon-
strate hepatic BMPR2 expression. Samples were obtainedfrom unused transplant donor
tissues, kept on ice, and then
stored frozen at 80°C until use.
Circulating iron parameters.
sTfR, GDF-15, and interleukin
(IL)-6 levels were determined by
enzyme-linked immunoadsor-
bent assay (R&D Systems Eu-
rope, Abingdon, Oxfordshire,
United Kingdom). Hepcidin lev-
els were determined by a com-
petitive radioimmunoassay, as
previously described (16). Eryth-
ropoietin (EPO) was measured
using an Immulite-2000 analyzer
(Siemens, Frimley, Surrey, United
Kingdom). All other measures
were determined by standard
clinical pathology accredited hospital assays. Iron deficiency
was defined by high levels of sTfR (normal range: 8.7 to
28.1 nmol/l), which are largely unaffected by inflammation
and thus provide a more robust peripheral marker of body
iron stores (17). Serum iron (normal range: male: 9 to 29
mol/l; female: 7 to 27 mol/l), transferrin saturation
20%), and ferritin (100 g/l) were also measured. The
ormal range of hepcidin was previously determined at 2 to
5 ng/ml and independently validated in a second group of
ealthy volunteers (18). EPO had a normal range of 3.3 to
6.6 mIU/ml. Anemia was assessed by hemoglobin mea-
urements (lower limits: females: 12 g/dl, males: 13 g/dl).
DW indexes were measured on the Sysmex-XE-2100
uto-analyzer (Sysmex, Wymbush, Milton Keynes, United
ingdom), a method based upon electrical impedance using
ydrodynamic focusing.
ell culture. HepG2 (human hepatocellular carcinoma)
ells (LGC Standards, Teddington, Middlesex, United King-
om) were seeded at 5  105 cells per well in 6-well plates in
minimum essential medium (MEM, Sigma-Aldrich,
Gillingham, Kent, United Kingdom) containing 10% fetal
bovine serum and antibiotics/antimicrotics. Short interfer-
ing RNA (siRNA) transfections were performed the follow-
ing day in OPTI-MEM medium, using Oligofectamine
(Invitrogen, Paisley, United Kingdom) and siRNA duplexes
that targeted a scrambled sequence or the type II BMP
receptors, BMPR2, ActRIIA and ActRIIB (Invitrogen).
Three days post-transfection, cells were treated with vehicle
or 10 ng/well rhBMP-6 (R&D Systems). Protein was
extracted in RIPA (radio-immunoprecipitation assay) buffer
(Sigma-Aldrich). RNA was extracted using the Trizol
method (Invitrogen).
Immunoblotting. Immunoblotting was performed using a
mouse monoclonal antibody for human BMPR2 at 1:400
dilution overnight at 4oC (BD Biosciences, Oxford, United
Kingdom) followed by anti-mouse IgG (GE Healthcare,
Amersham, Buckinghamshire, United Kingdom) at 1:2,000
Abbreviations
and Acronyms
ANOVA  analysis of
variance
IPAH  idiopathic
pulmonary arterial
hypertension
IQR  interquartile
range(s)
PAH  pulmonary arterial
hypertension
RDW  red cell distribution
width
siRNA  short interfering
RNA
WHO  World Health
Organizationfor 1 h at room temperature.
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Iron Deficiency in IPAH July 12, 2011:300–9Reverse-transcription PCR. RNA was reverse transcribed
sing Thermoscript reverse-transcription PCR (RT-PCR)
its (Invitrogen). Twenty nanograms of cDNA product was
sed with 10 l of PCR MasterMix (Promega, Southam-
pton, Hampshire, United Kingdom). Primers (annealing
temperatures and cycle number) were as follows: hepcidin
(60°C, 33 cycles) forward primer: 5=-GGCTCTGTTT-
TCCCACAACAG-3=, reverse: 5=-TCCTTCGCCTC-
TGGAACATGG-3=; Actin (60°C, 27 cycles) forward:
5=-CATGCCATCCTGCGTCTGGA-3=, reverse: 5=-
CCGTGGCCATCTCTTGCTCG-3=; BMPR2 (53°C,
33 cycles) forward: 5=-CTGCGGCTGCTTCGCAGA-
AT-3=, reverse: 5=-TGGTGTTGTGTCAGGAGGTGG-3=.
Data presentation and statistical analysis. Protein mea-
surements are displayed as dot-plots, bars indicate medians.
Clinical and hemodynamic data are presented as group
mean  SD, or as median values with interquartile ranges
(IQRs). Several variables were not normally distributed, as
shown by the Kolmogorov-Smirnov test, and were therefore
transformed to their natural logarithm (ln) or square root, as
appropriate to best normalize the data, before further
analysis. Continuous data across categorical variables were
compared by Kruskal-Wallis analysis of variance (ANOVA).
Correlations were assessed by the Spearman rank test. Cox
regression analyses identified prognostic predictors. Signif-
icant predictors from univariate analysis (p  0.05) were
then entered into a multivariable model. These variables
were compared by stepwise backward hazard ratios Cox
analysis; variables removed at p  0.10. RT-PCR results
were compared by ANOVA, with Tukey post-hoc analysis
performed if p  0.05. All calculations were performed
with SPSS version 17.0 (SPSS, Inc., Chicago, Illinois) or
GraphPad Prism4 (GraphPad Software Inc, La Jolla,
California).
Results
Iron deficiency is prevalent in IPAH. Subject character-
istics are detailed in Table 1. Circulating sTfR levels were
raised (median: 33.0 nmol/l, IQR: 23.0 to 43.0 nmol/l) in
IPAH, with 62 of 98 (63%) patients having levels above the
normal range (28.1 nmol/l) compared with 16.7% of
controls. sTfR levels were raised irrespective of warfarin
therapy (Online Fig. 1). Higher sTfR levels were observed in
IPAH versus controls across all age groups (Online Fig. 2A)
and irrespective of gender (Online Fig. 2B). Seventy of the
patients were British, but elevated levels could also be observed
in some patients in other ethnic groups (Online Fig. 3).
Low serum iron (8.7 mol/l, IQR: 5.0 to 14.0 mol/l)
nd ferritin (50.0 g/l, IQR: 27.5 to 142.0 g/l) levels were
resent in the IPAH patients and transferrin saturations
19.0%, IQR: 12.0% to 29.0%) were 20% in over one-half
f the patients assessed (Fig. 1). Levels in healthy volunteers
re detailed in Online Table 1. Although a large proportion
f the IPAH patients displayed features of iron deficiency,
hey were not overtly anemic, with mean hematocrit and cemoglobin levels of 0.47  0.06 and 14.7  2.5 g/dl
Fig. 1), and mean cell volume/hemoglobin values of 88.9
.1 fl and 29.8  3.1 pg, respectively. Median red cell
istribution width was 14.9% (IQR: 13.7% to 16.4%),
owards the upper end of the normal range (8.3% to 17.5%).
TfR and ferritin levels did not differ between patients on
ifferent PAH therapies (Online Table 2).
epcidin levels are abnormal in IPAH and relate to iron
tatus. Hepcidin levels were significantly higher in patients
ith IPAH, compared with healthy controls (34.5 ng/ml,
QR: 3.6 to 83.0 ng/ml; n  98 versus 25.5 ng/ml, IQR:
1.7 to 50.0 ng/ml; n  106; p  0.001), and 33 (34%)
atients had concentrations above the previously defined
pper limit of 55 ng/ml (Fig. 2A) (18). Hepcidin levels did
ot correlate with IL-6 values before (Online Fig. 4) or after
djusting for iron status (Fig. 2B), suggesting raised hepci-
in levels were not due to inflammation. In agreement with
his, no correlation was observed with C-reactive protein in
subgroup of patients where C-reactive protein measure-
ents were available (rho  0.02, p  0.92, n  45). In
contrast to healthy controls, where all hepcidin levels were
2 ng/ml, there was also a cohort of 21 (21%) IPAH
patients with hepcidin levels 2 ng/ml (Fig. 2A) that
exhibited marked iron deficiency (Figs. 2B and 2C).
hereas hepcidin levels were lowest in these patients,
Subject CharacteristicsTable 1 Subject Characteristics
IPAH
(n  98)
Controls
(n  106)
Age, yrs 47.1 15.5 34.2 9.9
Sex
Female 69 (70%) 52 (49%)
Male 29 (30%) 54 (51%)
Baseline mean pulmonary artery
pressure, mm Hg
56.1 12.7 —
Right atrial pressure, mm Hg 11.4 5.9 —
Pulmonary capillary wedge
pressure, mm Hg
12.1 5.3 —
Cardiac index, l/min/m2 2.01 (1.65–2.78)* —
Pulmonary artery O2 saturation, % 63.9 12.6 —
Pulmonary vascular resistance,
Woods units
14.1 9.4 —
WHO class
I 5 —
II 20 —
III 54 —
IV 19 —
6-min walk, m 282 161 —
Treatment
Naive 32 —
Warfarin 81 —
Bosentan 39 —
Sildenafil 17 —
Treprostinil 10 —
Values are mean  SD or n (%). Baseline details for study participants are shown. *Variable is not
normally distributed and therefore given as median (interquartile range).
IPAH  idiopathic pulmonary arterial hypertension; WHO  World Health Organization.orrelating inversely with sTfR (Fig. 2B) and positively with
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July 12, 2011:300–9 Iron Deficiency in IPAHincreasing ferritin levels (Fig. 2C), a significant proportion
of patients with iron deficiency displayed inappropriately
normal or even high hepcidin levels. Linear regression
modeling confirmed that IPAH patients had significantly
higher hepcidin levels than controls after adjusting for sTfR
levels (Fig. 2B) or ferritin and EPO levels (Online Table 3).
Hepcidin levels did not differ between subgroups on differ-
ent PAH-targeted therapies (Online Table 2).
Hepcidin stimulation by BMP-6 is increased by BMPR2
knockdown. Human hepatoma HepG2 cells express
both BMPR2 and hepcidin, and in response to BMP-6
stimulation, hepcidin mRNA expression and protein
secretion are significantly increased (Fig. 3). Knockdown
of BMPR2 by siRNA 3 days prior to treatment (Online
Fig. 5) augmented the response to BMP-6 (Fig. 3). This
augmentation was not seen when either activin receptor
type II A or B (ActRIIA and ActRIIB) were knocked
down with siRNA. Basal hepcidin expression was un-
changed. Significant BMPR2 expression was also dem-
onstrated in human liver tissue samples obtained from
unused donors (Fig. 3).
Erythropoietin is raised in IPAH and relates to lower
hepcidin levels. EPO levels were raised in the IPAH
Figure 1 Characterization of Iron Status in Patients With IPAH
Soluble transferrin receptor, iron, transferrin saturation, ferritin, and hemoglobin levels wer
Shaded areas delineated by dashed lines indicate normal ranges in healthy populationpopulation (17.3 IU/l, IQR: 12.1 to 43.0 IU/l vs. 9.7 IU/l,IQR: 7.4 to 12.6 IU/l in controls, p  0.001) and
correlated inversely with hepcidin (Figs. 4A and 4B).
EPO levels did not correlate with red blood cell counts,
hematocrit, nor hemoglobin levels, but did correlate with
RDW (rho  0.527, p  0.001). EPO levels did not
correlate with peripheral oxygen saturations or plasma
hemoglobin content, but did correlate inversely with the
product of these 2 measures (rho  0.357, p  0.006).
e found raised GDF-15 levels in patients with high
TfR (Table 2), which also correlated with increased
DW (rho  0.332, p  0.001). GDF-15 did not
orrelate with EPO (p  0.1) or hepcidin (p  0.8).
sTfR levels relate to functional class, exercise capacity
and survival in IPAH. sTfR levels were related to other
iron indexes, increased with WHO functional class (p 
0.0001) (Fig. 5A), and correlated negatively with 6-min
walk distance (Table 2). During the follow-up period, 39
patients died. Patients with raised sTfR (28.1 nmol/l) had
higher mortality (p  0.022) (Fig. 5B). sTfR levels pre-
dicted mortality in IPAH, and this was independent of
WHO functional class, 6-min walk distance, and age (p 
0.011) (Table 3). Whether patients were sampled before or
after treatment was commenced did not predict survival in
easured in plasma samples by standardized clinical pathology–accredited assays.
H  idiopathic pulmonary arterial hypertension.e all m
s. IPAthis group (p  0.09) (Table 3).
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The importance of iron regulation in cardiovascular disease
(19) and in the control of pulmonary vascular tone is now
recognized (2–4). We have identified iron deficiency without
overt anemia in a large proportion (approximately two-thirds)
of patients with IPAH, characterized primarily by raised
plasma sTfR, but also by reduced serum iron, transferrin
saturation, and ferritin levels and increased RDW.
Circulating soluble transferrin receptor levels are a sensitive
marker of tissue iron availability, which, unlike ferritin and
serum iron measurements, are unaffected by inflammation
(17). When iron deficiency is present, sTfR levels are increased
disproportionately to erythropoietic activity (20), as the bone
Figure 2 Hepcidin Levels in IPAH
(A) Circulating hepcidin levels in patients with idiopathic pulmonary arterial hypertensi
versus ln-scaled soluble transferrin receptor and ln-scaled ferritin levels in plasma frommarrow attempts to maximize iron uptake. For these reasons,sTfR is the best available circulating indicator of iron deficiency
in diseases with an inflammatory component, such as IPAH.
The cause of iron deficiency in IPAH is not immediately
clear. Three possibilities to be considered are chronic blood
loss, polycythemia due to the development of hypoxemia,
and insufficient iron absorption from the gut. The majority
of IPAH patients receive warfarin and are female, many of
whom are pre-menopausal, and this might implicate blood
loss. However, this is not a complete explanation. sTfR levels
were also raised in patients not taking warfarin and did not
significantly differ with gender nor age; women above age 60
years and men with IPAH also exhibited raised sTfR levels.
This agrees with the data of Ruiter et al. (7), who
H). Shaded area represents normal range. (B and C) Square root–scaled hepcidin
nts with IPAH and healthy controls.on (IPA
patieobserved an equal prevalence of iron deficiency in pre- and
R.
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July 12, 2011:300–9 Iron Deficiency in IPAHpost-menopausal women with IPAH and no reported
abnormal gastrointestinal or gynecological blood loss. Fur-
thermore, the distribution of plasma hepcidin levels in
Figure 3 Stimulation of Hepcidin Expression in HepG2 Cells by
(A) Reverse-transcription PCR (RT-PCR) data indicating hepcidin and actin express
by treatment with or without BMP-6 (10 ng/ml). (B and C) Hepcidin mRNA express
siRNA treatment. Results shown are from 3 experiments. (B) ***p  0.001 vers
(C) *p  0.05 and ***p  0.001 versus scram baseline. ###p  0.001 versus
and actin expression in HepG2 and human liver cDNA samples detected by RT-PCthe IPAH patient population is not consistent with bloodloss as a single cause; iron deficiency from chronic blood
loss would normally be associated with reduced circulating
hepcidin (21). The iron-deficient patients had lower periph-
-6 Is Exacerbated by BMPR2 Knockdown
lowing scramble (scram)/BMPR2 short interfering RNA (siRNA) treatment followed
d protein release data from HepG2 cells treated with or without BMP-6 following
trols. ###p  0.001 versus all other siRNA plus BMP-6 treatment groups.
BMP-6 and ActRIIBBMP-6, and p  0.05 versus ActRIIABMP-6. (D) BMPR2BMP
ion fol
ion an
us con
scrameral oxygen saturations, but in the absence of an associated
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Iron Deficiency in IPAH July 12, 2011:300–9increase in hemoglobin or hematocrit, it is unlikely that
reactive polycythemia could explain the deficiency seen.
Hepcidin inhibits dietary uptake and mobilization of iron
via degradation of the unique iron exporter, ferroportin, on
enterocytes and reticuloendothelial cells, respectively (8).
Figure 4 Erythropoietin Levels in IPAH
(A) Erythropoietin levels in patients with idiopathic pulmonary arterial hypertension
in plasma from patients with IPAH and from healthy controls.
Patient Characteristics Stratified by Normal/HigTable 2 Patient Characteristics Stratified b
Normal (8.7–28.1 nm
(n  36)
Age, yrs 45.5 16.0
6-min walk, m 340 156
WHO class
I/II 12
III 19
IV 5
Peripheral O2 sat., % 95.0 (93.0–98.0)*
O2 sat. post–6-min walk, % 95.0 (88.0–97.0)*
Iron, mol/l 13.0 (7.4–16.8)*
TIBC, mol/l 59.0 (55.0–67.0)*
Transferrin saturation, % 27.0 (18.8–35.1)*
Ferritin, g/l 66.5 (38.0–170.0)
sTfR/log ferritin 0.8 (0.7–1.0)*
Hepcidin, ng/ml 53.0 (31.5–102.5)
EPO, mIU/ml 12.5 (10.0–19.5)*
RBC, 1012/l 4.8 0.6
Hemoglobin, g/dl 15.3 1.7
Hematocrit 0.43 0.05
Red cell distribution width, % 13.9 (13.5–14.9)*
IL-6, pg/ml 2.1 (1.5–4.7)*
GDF-15, pg/ml 549 (350–875)*
NT-proBNP, ng/l 532 (186–1,031)*
Clinical and biochemical measures are stratified by the upper limit o
analysis of variance for World Health Organization class and Spearma
relationship. *Variable is not normally distributed and therefore givenNT-proBNP  N-terminal pro–B-type natriuretic peptide; RBC  red blood
capacity.The low or undetectable hepcidin levels observed in some of
the profoundly iron-deficient IPAH patients may represent
an attempt to increase dietary iron absorption. Hepcidin
levels raised or maintained at normal levels in the presence
of raised sTfR in a significant proportion of IPAH patients
). (B) Square root–scaled hepcidin versus ln-scaled erythropoietin levels
fR Levelsmal/High sTfR Levels
evels Spearman Rank Test
High (>28.1 nmol/l)
(n  62) Rho Sig.
48.1 15.7 0.11 0.37
247 154 0.39 0.03
13 N/A <0.05
35
14
93.5 (88.0–95.5)* 0.33 0.01
88.5 (80.0–95.0)* 0.34 0.03
7.7 (3.3–12.1)* 0.41 0.003
61.9 (47.3–68.0)* 0.09 0.53
15.6 (10.7–22.0)* 0.46 <0.001
43.0 (20.5–91.5)* 0.33 <0.001
1.9 (1.4–2.8)* 0.88 <0.001
14.4 (0.9–56.0)* 0.49 <0.001
32.5 (14.8–52.0)* 0.50 <0.001
5.3 0.6 0.23 0.07
14.4 2.8 0.28 0.008
0.45 0.04 0.06 0.50
15.7 (14.4–17.6)* 0.57 <0.001
5.6 (2.9–10.8)* 0.46 <0.001
915 (359–1,860)* 0.26 0.01
838 (410–1,448)* 0.13 0.04
ormal range (28.1 nmol/l). Statistics shown are from Kruskal-Wallis
correlations for all other parameters. Bold type indicates significant
dian (interquartile range).(IPAHh sTy Nor
sTfR L
ol/l)
*
*
f the n
n rank
as mecells; sTfR  soluble transferrin receptor; TIBC  total iron binding
s
w
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tribute to the iron deficiency by inhibiting dietary iron
uptake. This hypothesis is supported by the observation that
only a small proportion of IPAH patients respond to oral
iron therapy (7).
Regulation of hepcidin production in IPAH. In the
investigation of the factors underlying elevated hepcidin
levels in IPAH, 3 mechanisms were considered: inflamma-
tion, BMP signaling, and erythropoietic activity.
Inflammation can raise hepcidin levels, primarily through
IL-6 induction (22), and raised hepcidin production under-
lies anemia of chronic disease (23). IL-6 levels were raised in
IPAH versus controls, and despite low serum iron and
transferrin saturations, most patients had ferritin levels
within the normal range, indicating that inflammation was
present in these patients to a certain degree. However, sTfR
levels were raised, and plasma hepcidin did not correlate
with IL-6 in IPAH patients whether or not iron status was
taken into account by considering sTfR or ferritin levels in
Figure 5 sTfR Levels in IPAH
(A) Distribution of soluble transferrin receptor (sTfR) levels according to World Hea
p value relates to Kruskal-Wallis ANOVA. (B) Kaplan-Meier survival estimates strat
upper limit of the normal range, 28.1 nmol/l.
Cox Regression Survival AnalysisTable 3 Cox Regression Survival Analysis
Variable
Simple
Hazard Ratio (95%
Age (per 10 yrs) 1.387 (1.128–1.7
WHO functional class
I/II vs. IV 0.133 (0.038–0.4
III vs. IV 0.535 (0.277–1.0
6-min walk distance (per 100 m) 0.618 (0.499–0.7
Ln[Soluble transferrin receptor] 2.449 (1.292–4.6
Peripheral artery O2 saturation, % 0.955 (0.901–1.0
Treated versus treatment naive 1.289 (0.961–1.7
Simple model indicates predictive power of individual variables. Sign
covariate model, which was developed by the backwards stepwise ha
ln-transformation before entry into the model. Bold type indicates significan
CI  confidence interval; WHO  World Health Organization.parallel. This is inconsistent with anemia of chronic disease,
where ferritin levels are normal or increased and sTfR levels
repressed (23). Combined, our data suggest that inflamma-
tion and IL-6 stimulation, though present, are not the main
cause of raised hepcidin levels in IPAH.
BMP signaling may link IPAH and dysregulated hepci-
din production. BMPR2 protein expression is reduced in all
patients with IPAH (9), and loss-of-function mutations in
BMPR2 increase susceptibility to the development of PAH
(10). In human liver, BMP-6 signaling is postulated to
involve ActRIIA rather than BMPR2 receptors (24), but
down-regulation of BMPR2 can increase BMP-6 and -7
signaling through ActRIIA (25). Indeed, using hepatocel-
lular carcinoma cells, we have shown that BMPR2, but not
ActRIIA or ActRIIB, knockdown leads to a concomitant
increase in hepcidin production in response to BMP-6
stimulation. We also demonstrated BMPR2 mRNA expres-
ion in 5 of 5 of the human liver samples we examined,
hich has not previously been shown (24). Down-
ganization (WHO) functional class in patients with IPAH and in healthy controls.
y sTfR level below (blue solid line) or above (green dashed line) the pre-defined
l Multiple Covariate Model
Sig. Hazard Ratio (95% CI) Sig.
0.002 0.493
0.005 0.105
0.001 0.653 (0.515–0.828) <0.001
0.006 2.569 (1.240–5.320) 0.011
0.118
0.090
redictors from univariate analysis were then entered into a multiple
tios analysis method. Soluble transferrin receptor was normalized bylth Or
ified bMode
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07)
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42)
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ificant p
zard rat relationship.
m
i
h
r
I
i
v
s
i
t
p
t
h
t
h
t
a
v
m
f
(
308 Rhodes et al. JACC Vol. 58, No. 3, 2011
Iron Deficiency in IPAH July 12, 2011:300–9regulation of BMPR2 may augment plasma hepcidin levels
in PAH, predicting that familial PAH may be associated
with more severe iron deficiency and increased hepcidin
expression.
Erythropoietic activity inhibits hepcidin expression under
anemic conditions (26) and is impaired in anemia of chronic
disease (23). Serum from patients with overactive erythro-
poiesis inhibits hepcidin expression in vitro (27) and recom-
binant human EPO administration lowers hepcidin levels in
healthy volunteers (28). Dysfunctional erythropoiesis or
erythropoietic signaling could contribute to inappropriately
increased hepcidin levels. EPO levels correlated inversely
with hepcidin in IPAH patients, consistent with a model
where EPO directly or indirectly inhibits hepcidin produc-
tion. EPO does not suppress hepatocyte hepcidin levels in
vitro (29), and other circulating factors implicated as pos-
sible mediators include GDF-15 (27), a TGF- superfamily
ember that is elevated in IPAH (30). GDF-15 was raised
n iron-deficient patients, but did not correlate with EPO or
epcidin levels, suggesting GDF-15 is not important in
egulating hepcidin in IPAH.
ron status and pulmonary hypertension. sTfR levels
ncreased significantly with disease severity, correlated in-
ersely with exercise capacity, and independently predicted
urvival after adjustments for standard clinical measures
ncluding 6-min walk distance and WHO class. These data,
ogether with the recent observation that RDW and anemia
redict mortality in pulmonary hypertension (5,6), suggest
hat iron deficiency is clinically relevant in IPAH.
Iron status influences pulmonary vascular responses to
ypoxia. Iron chelation elevates pulmonary vascular resis-
ance in humans (2) and increases sensitivity to acute
ypoxic exposure (3). Iron deficiency induced by venesec-
ion also exacerbates pulmonary vasoconstriction at high
ltitude (4), whereas iron infusion reduces these pulmonary
asopressor responses (3,4). The underlying mechanism
ay involve normoxic stabilization of hypoxia inducible
actors (HIF) as HIF hydroxylases require iron as a cofactor
31,32). HIF-–deficient mice develop less severe pulmo-
nary hypertension and vascular remodeling when exposed
to chronic hypoxia (33,34), and pulmonary endothelial
HIF-1 expression is increased in PAH (35). By preventing
HIF activation, iron replacement therapy may potentially
reduce pulmonary endothelial dysfunction, HIF-dependent
gene activation, and vascular remodeling in pulmonary
hypertension.
Iron repletion increases exercise capacity and reduces
New York Heart Association functional class in left heart
failure (19,36,37). Contrary to previous observations (36),
improvements were similar in patients irrespective of ane-
mia (19). Coupled with our findings, this paves the way for
a study investigating the role of iron-replacement therapy in
IPAH.
Study limitations. One limitation of this study is the lack
of longitudinal data; it would be of interest to investigate
the onset and time course of iron deficiency in IPAH.The control population in this study was younger and
contained a more equal distribution of sexes; however,
gender differences in hepcidin are related to lower ferritin
levels in younger women, hence no gender-dependent
differences in iron parameters were observed. The lack of
occult blood stool measurements and gynecological ques-
tionnaire limits our ability to rule out bleeding as a cause
of iron deficiency in IPAH. There is no reason to believe
that our patients were receiving a poor diet. Furthermore,
Ruiter et al. (7) found that more than one-half of IPAH
patients who received oral iron therapy were unrespon-
sive, suggesting that absorption, rather than dietary
content, is a significant problem in IPAH. The survival
analysis included patients who had commenced therapy.
When this was analyzed as a factor, survival did not
significantly differ between treated and treatment-naive
groups. We would also like to emphasize that we are not
suggesting sTfR levels should be utilized as a prognostic
biomarker in IPAH, but that it illustrates the clinical
relevance of iron deficiency. Although we elected to study
only those patients with IPAH, it would be of interest for
further studies to investigate the prevalence and clinical
significance of iron deficiency in other forms of PAH to
determine the potential for therapeutic intervention.
Conclusions
We have characterized iron deficiency in a significant
proportion of patients with IPAH and demonstrate a
relationship between sTfR levels and disease severity and
outcome. Inappropriately raised hepcidin levels may con-
tribute to the development of iron deficiency in some
patients with IPAH. Importantly, iron status represents
an accessible target for novel therapeutic intervention.
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